161 related articles for article (PubMed ID: 19201468)
1. p53 nuclear accumulation is associated with extramedullary progression of multiple myeloma.
Sheth N; Yeung J; Chang H
Leuk Res; 2009 Oct; 33(10):1357-60. PubMed ID: 19201468
[TBL] [Abstract][Full Text] [Related]
2. Primary extramedullary plasmacytoma and multiple myeloma: phenotypic differences revealed by immunohistochemical analysis.
Kremer M; Ott G; Nathrath M; Specht K; Stecker K; Alexiou C; Quintanilla-Martinez L; Fend F
J Pathol; 2005 Jan; 205(1):92-101. PubMed ID: 15586381
[TBL] [Abstract][Full Text] [Related]
3. Cell cycle regulators in multiple myeloma: prognostic implications of p53 nuclear accumulation.
Pruneri G; Carboni N; Baldini L; Intini D; Colombi M; Bertolini F; Valentini S; Maisonneuve P; Viale G; Neri A
Hum Pathol; 2003 Jan; 34(1):41-7. PubMed ID: 12605365
[TBL] [Abstract][Full Text] [Related]
4. Features of extramedullary disease of multiple myeloma: high frequency of p53 deletion and poor survival: a retrospective single-center study of 834 cases.
Deng S; Xu Y; An G; Sui W; Zou D; Zhao Y; Qi J; Li F; Hao M; Qiu L
Clin Lymphoma Myeloma Leuk; 2015 May; 15(5):286-91. PubMed ID: 25640025
[TBL] [Abstract][Full Text] [Related]
5. Association between intracranial plasmacytoma and multiple myeloma: clinicopathological outcome study.
Schwartz TH; Rhiew R; Isaacson SR; Orazi A; Bruce JN
Neurosurgery; 2001 Nov; 49(5):1039-44; discussion 1044-5. PubMed ID: 11846895
[TBL] [Abstract][Full Text] [Related]
6. Plasmacytoma in patients with multiple myeloma: morphology and immunohistochemistry.
Firsova MV; Mendeleeva LP; Kovrigina AM; Solovev MV; Savchenko VG
BMC Cancer; 2020 Apr; 20(1):346. PubMed ID: 32321465
[TBL] [Abstract][Full Text] [Related]
7. P53 deletion may drive the clinical evolution and treatment response in multiple myeloma.
López-Anglada L; Gutiérrez NC; García JL; Mateos MV; Flores T; San Miguel JF
Eur J Haematol; 2010 Apr; 84(4):359-61. PubMed ID: 20002730
[TBL] [Abstract][Full Text] [Related]
8. Alterations in the Transcriptional Programs of Myeloma Cells and the Microenvironment during Extramedullary Progression Affect Proliferation and Immune Evasion.
Ryu D; Kim SJ; Hong Y; Jo A; Kim N; Kim HJ; Lee HO; Kim K; Park WY
Clin Cancer Res; 2020 Feb; 26(4):935-944. PubMed ID: 31558476
[TBL] [Abstract][Full Text] [Related]
9. A retrospective study of correlation of morphologic patterns, MIB1 proliferation index, and survival analysis in 134 cases of plasmacytoma.
Ghodke K; Shet T; Epari S; Sengar M; Menon H; Gujral S
Ann Diagn Pathol; 2015 Jun; 19(3):117-23. PubMed ID: 25842207
[TBL] [Abstract][Full Text] [Related]
10. Single-cell RNA sequencing reveals chemokine self-feeding of myeloma cells promotes extramedullary metastasis.
Geng S; Wang J; Zhang X; Zhang JJ; Wu F; Pang Y; Zhong Y; Wang J; Wang W; Lyu X; Huang Y; Jing H
FEBS Lett; 2020 Feb; 594(3):452-465. PubMed ID: 31561267
[TBL] [Abstract][Full Text] [Related]
11. Regulation of the CD56 promoter and its association with proliferation, anti-apoptosis and clinical factors in multiple myeloma.
Damgaard T; Knudsen LM; Dahl IM; Gimsing P; Lodahl M; Rasmussen T
Leuk Lymphoma; 2009 Feb; 50(2):236-46. PubMed ID: 19235015
[TBL] [Abstract][Full Text] [Related]
12. CD31 (JC70) expression in plasma cells: an immunohistochemical analysis of reactive and neoplastic plasma cells.
Govender D; Harilal P; Dada M; Chetty R
J Clin Pathol; 1997 Jun; 50(6):490-3. PubMed ID: 9378815
[TBL] [Abstract][Full Text] [Related]
13. Possible roles for activating RAS mutations in the MGUS to MM transition and in the intramedullary to extramedullary transition in some plasma cell tumors.
Rasmussen T; Kuehl M; Lodahl M; Johnsen HE; Dahl IM
Blood; 2005 Jan; 105(1):317-23. PubMed ID: 15339850
[TBL] [Abstract][Full Text] [Related]
14. Genetic Basis of Extramedullary Plasmablastic Transformation of Multiple Myeloma.
Liu Y; Jelloul F; Zhang Y; Bhavsar T; Ho C; Rao M; Lewis NE; Cimera R; Baik J; Sigler A; Sen F; Yabe M; Roshal M; Landgren O; Dogan A; Xiao W
Am J Surg Pathol; 2020 Jun; 44(6):838-848. PubMed ID: 32118627
[TBL] [Abstract][Full Text] [Related]
15. Differential expression of CD56 and CD44 in the evolution of extramedullary myeloma.
Dahl IM; Rasmussen T; Kauric G; Husebekk A
Br J Haematol; 2002 Feb; 116(2):273-7. PubMed ID: 11841427
[TBL] [Abstract][Full Text] [Related]
16. Circulating Serum MicroRNA-130a as a Novel Putative Marker of Extramedullary Myeloma.
Besse L; Sedlarikova L; Kryukov F; Nekvindova J; Radova L; Slaby O; Kuglik P; Almasi M; Penka M; Krejci M; Adam Z; Pour L; Sevcikova S; Hajek R
PLoS One; 2015; 10(9):e0137294. PubMed ID: 26389804
[TBL] [Abstract][Full Text] [Related]
17. Cytogenetics of extramedullary manifestations in multiple myeloma.
Billecke L; Murga Penas EM; May AM; Engelhardt M; Nagler A; Leiba M; Schiby G; Kröger N; Zustin J; Marx A; Matschke J; Tiemann M; Goekkurt E; Heidtmann HH; Vettorazzi E; Dierlamm J; Bokemeyer C; Schilling G
Br J Haematol; 2013 Apr; 161(1):87-94. PubMed ID: 23368088
[TBL] [Abstract][Full Text] [Related]
18. Cytogenetics in multiple myeloma patients progressing into extramedullary disease.
Besse L; Sedlarikova L; Greslikova H; Kupska R; Almasi M; Penka M; Jelinek T; Pour L; Adam Z; Kuglik P; Krejci M; Hajek R; Sevcikova S
Eur J Haematol; 2016 Jul; 97(1):93-100. PubMed ID: 26432667
[TBL] [Abstract][Full Text] [Related]
19. FAM46C-mediated tumor heterogeneity predicts extramedullary metastasis and poorer survival in multiple myeloma.
Zhang W; Wu C; Geng S; Wang J; Yan C; Zhang X; Zhang JJ; Wu F; Pang Y; Zhong Y; Wang J; Fu W; Huang X; Wang W; Lyu X; Huang Y; Jing H
Aging (Albany NY); 2023 May; 15(9):3644-3677. PubMed ID: 37155154
[TBL] [Abstract][Full Text] [Related]
20. Clinical analysis of 36 multiple myeloma patients with extramedullary plasmacytoma invasion of the spinal canal.
Zhang J; Zhong Y
Hematol Oncol; 2015 Jun; 33(2):75-9. PubMed ID: 24395149
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
